Table 1.
Baseline patient characteristics of 181 patients with advanced gastric cancer receiving adjuvant chemotherapy, stratified by PSM.
| Variables | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| Doublet | S1 | p Value | Doublet | S1 | p Value | |
| N = 117 | N = 64 | N = 64 | N = 64 | |||
| Age | 0.023 | 0.476 | ||||
| ≤65 | 82 (70%) | 34 (53%) | 38 (59%) | 34 (53%) | ||
| >65 | 35 (30%) | 30 (47%) | 26 (41%) | 30 (47%) | ||
| Gender | 0.034 | 0.277 | ||||
| Male | 84 (72%) | 36 (56%) | 42 (66%) | 36 (56%) | ||
| Female | 33 (28%) | 28 (44%) | 12 (34%) | 28 (44%) | ||
| Performance status | 0.008 | 0.57 | ||||
| 0–1 | 97 (83%) | 42 (66%) | 45 (70%) | 42 (66%) | ||
| 2–3 | 20 (17%) | 22 (34%) | 19 (30%) | 22 (34%) | ||
| Differentiation | 0.133 | 1 | ||||
| W/MD | 28 (24%) | 22 (34%) | 22 (34%) | 22 (34%) | ||
| PD/SRC | 89 (76%) | 42 (66%) | 42 (66%) | 42 (66%) | ||
| Surgery | 0.758 | 0.639 | ||||
| Total gastrectomy | 20 (17%) | 12 (19%) | 10 (16%) | 12 (19%) | ||
| Subtotal gastrectomy | 97 (83%) | 52 (81%) | 54 (84%) | 52 (81%) | ||
| Pathologic T stage | 0.214 | 0.639 | ||||
| 1–2 | 10 (9%) | 12 (19%) | 10 (16%) | 12 (19%) | ||
| 3–4 | 107 (91%) | 52 (81%) | 54 (84%) | 52 (81%) | ||
| Pathologic N stage | 0.371 | 0.211 | ||||
| 0–1 | 28 (24%) | 18 (28%) | 12 (19%) | 18 (28%) | ||
| 2–3 | 89 (76%) | 46 (72%) | 52 (81%) | 46 (72%) | ||
| Pathologic stage | 0.676 | 0.676 | ||||
| II | 26 (22%) | 16 (25%) | 14 (22%) | 16 (25%) | ||
| III | 91 (78%) | 48 (75%) | 50 (78%) | 48 (75%) | ||
| LN ratio | 0.042 | 0.111 | ||||
| ≤0.21 | 51 (43%) | 38 (59%) | 29 (45%) | 38 (59%) | ||
| >0.21 | 66 (57%) | 26 (41%) | 35 (55%) | 26 (41%) | ||
| median LN removed | 15 | 18 | 16 | 18 | ||
PSM–propensity score match; W/MD–well/moderately differentiated; PD/SRC–poorly differentiated/signet ring cell; LN, lymph node.